Concepedia

D. Bomba

DB

3

Publications

54

Citations

3

H-Index

2011

Active since

Affiliations

The Ohio State University Wexner Medical Center(Current)

D. Bomba is an author at The Ohio State University Wexner Medical Center specializing in cancer therapeutics, radiation oncology, and quantitative pharmacology.

Top concepts

Publications per year

2011–2021

3

Publications

3

AB0509 Kzr-616, a selective inhibitor of the immunoproteasome, shows a promising safety and target inhibition profile in a phase i, double-blind, single (SAD) and multiple ascending dose (MAD) study in healthy volunteers

Jason D. Lickliter, D. Bomba, Janet L. Anderl et al. · Annals of the Rheumatic Diseases · 2018 · 23 citations · Full text

A phase I, open-label, dose-escalation study of the novel oral proteasome inhibitor (PI) ONX 0912 in patients with advanced refractory or recurrent solid tumors.

Kyriakos P. Papadopoulos, David S. Mendelson, A. W. Tolcher et al. · Journal of Clinical Oncology · 2011 · 20 citations

, , +15

POS0695 KZR-616, A SELECTIVE IMMUNOPROTEASOME INHIBITOR FOR THE TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS: RESULTS FROM THE COMPLETED DOSE ESCALATION PHASE 1B PORTION OF THE MISSION STUDY

R. Furie, Samir V. Parikh, J. Wang et al. · Annals of the Rheumatic Diseases · 2021 · 11 citations

Rows per page

1–3 of 3